Pneumonia Testing Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	115 Pages	Fortune Business Insights Pvt. Ltd.	October, 2024	FOB19224152

Best Price Guarantee
Price	from $4,850
Length	115 Pages
Publisher	Fortune Business Insights Pvt. Ltd.
Published Date	October, 2024
SKU	FOB19224152

Pneumonia Testing Market

Growth Factors of Pneumonia Testing Market

The pneumonia testing market size was valued at USD 639.9 billion in 2023, and the market is now projected to grow from USD 676.1 billion in 2024 to USD 122.0 billion by 2032, exhibiting a CAGR of 6.5% during the forecast period of 2023-2030.

Government has put restrictions on social gatherings, events and moving out from home which make the people homesick. Numerous companies are encountering hurdles due to covid pandemic as the outbreak situation has curtailed production and supply chain which has hindered the pneumonia testing market switched to treating covid patients as priority over the other procedures which led the market growth.

Pneumonia's rising prevalence and concerns about its mortality will fuel pneumonia testing market growth. Rising prevalence of pneumonia promoting market growth. Pneumonia is generally more common in the elderly and pediatric populations.

Increasing acceptance and use of point-of-care and rapid testing to set growth trajectories. Regarding the market trends for pneumonia testing, there has been a change in consumer preferences and a rise in the need for point-of-care diagnostics over time. There is an urgent demand for quick diagnostic tools due to the increased incidence of pneumonia. Convenience, speedier diagnosis, and better treatment results are some of the main advantages linked to the point-of-care testing market, which encourages both patient and healthcare professional adoption. The study compared a conventional diagnostic method with commercially available syndromic diagnostic testing platforms, such as Filmarray Pneumonia panel and Unyvero, and discovered that the former two products were more effective in detecting pneumonia.

Comprehensive Analysis of Pneumonia Testing Market

The pneumonia testing market and healthcare industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the pharmacy benefit management industry. These segmentations are methodically segregated by product type, by type and by end users. The product types segmentation includes, Instruments and Reagents & Consumables while by Type segmentation includes Streptococcus-based, Legionella-based, Chlamydophila-based, Viral Pneumonia-based, Mycoplasma Pneumonia-based, and Others. However, the end users segmentation includes Hospitals & Clinics, Diagnostic Centers, and others.

The North America region lead the pneumonia testing market by benefitting a market size of USD 254.3 billion in 2023 due to significant number of instances of pneumonia, quick adoption of point-of-care technologies, advantageous reimbursement guidelines, the existence of large companies in the country, and the introduction of cutting-edge products.

The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These players include, Quidel Corporation (U.S.), Abbott (U.S.), bioMérieux SA (France), Thermo Fisher Scientific Inc. (U.S.), INTEC (China), OpGen (U.S.), Meridian Bioscience, Inc. (U.S.), BD (Becton, Dickinson, and Company) (U.S.), Luminex Corporation (DiaSorin S.p.A.) (U.S.) these market players provide a level-playing competitive landscape.

In December 2023, For the purification and isolation of bacterial and viral pathogens from respiratory biological materials, Thermo Fisher Scientific, Inc. launched the KingFisher Apex Dx, an automated nucleic acid purification equipment, and the Applied Biosystems MagMAX Dx Viral/Pathogen NA Isolation Kit.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 6.5% from 2024-2032

Unit Value (USD Million)

Segmentation By Product Type

Instruments
Reagents & Consumables

By Type

Streptococcus-based
Legionella-based
Chlamydophila-based
Viral Pneumonia-based
Mycoplasma Pneumonia-based
Others

By End-user

Hospitals & Clinics
Diagnostic Centers
Others

By Geography

North America (Product Type, Type, End-user, and By Country)
U.S.
Canada
Europe (Product Type, Type, End-user, and By Country/Sub-Region)
Germany
France
U.K.
Italy
Spain,
Russia
Nordic
Rest of Europe
Asia Pacific (Product Type, Type, End-user, and By Country/Sub-Region)
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia Pacific
Latin America (Product Type, Type, End-user, and By Country/Sub-Region)
Brazil
Mexico
Rest of Latin America
Middle East & Africa (Product Type, Type, End-user, and By Country/Sub-Region)
Turkey
Saudi Arabia
UAE
South Africa
Rest of Middle East & Africa

Please Note: It will take 5-6 business days to complete the report upon order confirmation.

1. Introduction: 1.1. Research Scope; 1.2. Market Segmentation; 1.3. Research Methodology; 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics: 3.1. Market Drivers; 3.2. Market Restraints; 3.3. Market Opportunities; 3.4. Market Trends
4. Key Insights: 4.1. Prevalence/Incidence of Pneumonia, By Key Countries, 2023; 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships etc.); 4.3. New Product Launches; 4.4. Overview: Technological Advancements in Pneumonia Testing Market; 4.5. Regulatory & Reimbursement Scenario, By Key Regions; 4.6. Impact of COVID-19 on Global Pneumonia Testing Market
5. Global Pneumonia Testing Market Analysis, Insights and Forecast, 2019-2032: 5.1. Market Analysis, Insights and Forecast – By Product Type; 5.1.1. Instruments; 5.1.2. Reagents & Consumables; 5.2. Market Analysis, Insights and Forecast – By Type; 5.2.1. Streptococcus-based; 5.2.2. Legionella-based; 5.2.3. Chlamydophila-based; 5.2.4. Viral Pneumonia-based; 5.2.5. Mycoplasma Pneumonia-based; 5.2.6. Others; 5.3. Market Analysis, Insights and Forecast – By End-User; 5.3.1. Hospitals & Clinics; 5.3.2. Diagnostic Centres; 5.3.3. Others; 5.4. Market Analysis, Insights and Forecast – By Region; 5.4.1. North America; 5.4.2. Europe; 5.4.3. Asia Pacific; 5.4.4. Latin America; 5.4.5. Middle East & Africa
6. North America Pneumonia Testing Market Analysis, Insights and Forecast, 2019-2032: 6.1. Market Analysis, Insights and Forecast – By Product Type; 6.1.1. Instruments; 6.1.2. Reagents & Consumables; 6.2. Market Analysis, Insights and Forecast – By Type; 6.2.1. Streptococcus-based; 6.2.2. Legionella-based; 6.2.3. Chlamydophila-based; 6.2.4. Viral Pneumonia-based; 6.2.5. Mycoplasma Pneumonia-based; 6.2.6. Others; 6.3. Market Analysis, Insights and Forecast – By End-User; 6.3.1. Hospitals & Clinics; 6.3.2. Diagnostic Centres; 6.3.3. Others; 6.4. Market Analysis, Insights and Forecast – By Country; 6.4.1. U.S.; 6.4.2. Canada
7. Europe Pneumonia Testing Market Analysis, Insights and Forecast, 2019-2032: 7.1. Market Analysis, Insights and Forecast – By Product Type; 7.1.1. Instruments; 7.1.2. Reagents & Consumables; 7.2. Market Analysis, Insights and Forecast – By Type; 7.2.1. Streptococcus-based; 7.2.2. Legionella-based; 7.2.3. Chlamydophila-based; 7.2.4. Viral Pneumonia-based; 7.2.5. Mycoplasma Pneumonia-based; 7.2.6. Others; 7.3. Market Analysis, Insights and Forecast – By End-User; 7.3.1. Hospitals & Clinics; 7.3.2. Diagnostic Centres; 7.3.3. Others; 7.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region; 7.4.1. Germany; 7.4.2. France; 7.4.3. U.K.; 7.4.4. Italy; 7.4.5. Spain; 7.4.6. Russia; 7.4.7. Nordic; 7.4.8. Rest of Europe
8. Asia Pacific Pneumonia Testing Market Analysis, Insights and Forecast, 2019-2032: 8.1. Market Analysis, Insights and Forecast – By Product Type; 8.1.1. Instruments; 8.1.2. Reagents & Consumables; 8.2. Market Analysis, Insights and Forecast – By Type; 8.2.1. Streptococcus-based; 8.2.2. Legionella-based; 8.2.3. Chlamydophila-based; 8.2.4. Viral Pneumonia-based; 8.2.5. Mycoplasma Pneumonia-based; 8.2.6. Others; 8.3. Market Analysis, Insights and Forecast – By End-User; 8.3.1. Hospitals & Clinics; 8.3.2. Diagnostic Centres; 8.3.3. Others; 8.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region; 8.4.1. China; 8.4.2. Japan; 8.4.3. South Korea; 8.4.4. Southeast Asia; 8.4.5. India; 8.4.6. Australia; 8.4.7. Rest of Asia Pacific
9. Latin America Pneumonia Testing Market Analysis, Insights and Forecast, 2019-2032: 9.1. Market Analysis, Insights and Forecast – By Product Type; 9.1.1. Instruments; 9.1.2. Reagents & Consumables; 9.2. Market Analysis, Insights and Forecast – By Type; 9.2.1. Streptococcus-based; 9.2.2. Legionella-based; 9.2.3. Chlamydophila-based; 9.2.4. Viral Pneumonia-based; 9.2.5. Mycoplasma Pneumonia-based; 9.2.6. Others; 9.3. Market Analysis, Insights and Forecast – By End-User; 9.3.1. Hospitals & Clinics; 9.3.2. Diagnostic Centres; 9.3.3. Others; 9.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region; 9.4.1. Brazil; 9.4.2. Mexico; 9.4.3. Rest of Latin America
10. Middle East & Africa Pneumonia Testing Market Analysis, Insights and Forecast, 2019-2032: 10.1. Market Analysis, Insights and Forecast – By Product Type; 10.1.1. Instruments; 10.1.2. Reagents & Consumables; 10.2. Market Analysis, Insights and Forecast – By Type; 10.2.1. Streptococcus-based; 10.2.2. Legionella-based; 10.2.3. Chlamydophila-based; 10.2.4. Viral Pneumonia-based; 10.2.5. Mycoplasma Pneumonia-based; 10.2.6. Others; 10.3. Market Analysis, Insights and Forecast – By End-User; 10.3.1. Hospitals & Clinics; 10.3.2. Diagnostic Centres; 10.3.3. Others; 10.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region; 10.4.1. Turkey; 10.4.2. Saudi Arabia; 10.4.3. UAE; 10.4.4. South Africa; 10.4.5. Rest of Middle East & Africa
11. Competitive Analysis: 11.1. Global Market Share Analysis (2023); 11.2. Company Profiles; 11.2.1. Quidel Corporation; 11.2.1.1. Overview; 11.2.1.2. Products & Services; 11.2.1.3. SWOT Analysis; 11.2.1.4. Recent Developments; 11.2.1.5. Strategies; 11.2.1.6. Financials (Based on Availability); 11.2.2. Abbott; 11.2.2.1. Overview; 11.2.2.2. Products & Services; 11.2.2.3. SWOT Analysis; 11.2.2.4. Recent Developments; 11.2.2.5. Strategies; 11.2.2.6. Financials (Based on Availability); 11.2.3. bioMérieux SA; 11.2.3.1. Overview; 11.2.3.2. Products & Services; 11.2.3.3. SWOT Analysis; 11.2.3.4. Recent Developments; 11.2.3.5. Strategies; 11.2.3.6. Financials (Based on Availability); 11.2.4. Thermo Fisher Scientific Inc.; 11.2.4.1. Overview; 11.2.4.2. Products & Services; 11.2.4.3. SWOT Analysis; 11.2.4.4. Recent Developments; 11.2.4.5. Strategies; 11.2.4.6. Financials (Based on Availability); 11.2.5. INTEC; 11.2.5.1. Overview; 11.2.5.2. Products & Services; 11.2.5.3. SWOT Analysis; 11.2.5.4. Recent Developments; 11.2.5.5. Strategies; 11.2.5.6. Financials (Based on Availability); 11.2.6. OpGen; 11.2.6.1. Overview; 11.2.6.2. Products & Services; 11.2.6.3. SWOT Analysis; 11.2.6.4. Recent Developments; 11.2.6.5. Strategies; 11.2.6.6. Financials (Based on Availability); 11.2.7. Meridian Bioscience, Inc.; 11.2.7.1. Overview; 11.2.7.2. Products & Services; 11.2.7.3. SWOT Analysis; 11.2.7.4. Recent Developments; 11.2.7.5. Strategies; 11.2.7.6. Financials (Based on Availability); 11.2.8. BD (Becton, Dickinson, and Company); 11.2.8.1. Overview; 11.2.8.2. Products & Services; 11.2.8.3. SWOT Analysis; 11.2.8.4. Recent Developments; 11.2.8.5. Strategies; 11.2.8.6. Financials (Based on Availability); 11.2.9. Luminex Corporation (DiaSorin S.p.A.); 11.2.9.1. Overview; 11.2.9.2. Products & Services; 11.2.9.3. SWOT Analysis; 11.2.9.4. Recent Developments; 11.2.9.5. Strategies; 11.2.9.6. Financials (Based on Availability)